2013;54(5):3333-3339.23599328 Sechi G, Deledda MG, Bua G, et al
3 Diabetes, cardiovascular disease and obesity are independent risk factors for CKD and represent a major global health burden
Stem Cell Res Ther 15 , 439 (2024)
Thus, these molecules reinforce antioxidant defense both transcriptionally and metabolically, closing the feedback loop between IR, OS, and cellular dysfunction in PCOS
Other Indications Under Study Phase 3 trials are ongoing for retatrutide in obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease, chronic kidney disease in patients with type 2 diabetes, and cardiovascular outcomes
First approved by the FDA to manage type 2 diabetes as Ozempic, later approved at a higher dose as Wegovy specifically for chronic weight management